Latest news

• FDA sets August review date for Teva's movement disorder drug

  Huntington's disease is a much smaller market than TD but that has not stopped the only approved drug for the condition - Lundbeck's Xenazine (tetrabenazine) - bring in sales of $330m

• FDA turns down Teva's Huntington's disease drug

  Teva's drug is a 'deuterated' form of VMAT-2 inhibitor tetrabenazine - the active ingredient in Lundbeck's already-approved Xenazine product - with a modified structure that seeks to improve the ... Xenazine is the only approved treatment for

• Teva drug shows promise in movement disorder

  While there is no FDA-approved drug for TD, the drug from which Teva's candidate is derived - Lundbeck's Xenazine (tetrabenazine) - has been used off-label to treat symptoms but

• Teva starts M&A push with $3.5bn Auspex buy

  It is also relatively low risk, as the non-deuterated form of tetrabenazine is already sold as Xenazine by Lundbeck as a treatment for Huntington's and achieved sales of ... Moreover, it may also allow a quick route to market by referencing Xenazine data

• Lundbeck still feeling effects from Cipralex patent loss

  Leading the upward trend was Xenazine (tetrabenazine) for the treatment of chorea associated with Huntington's disease - up 27% to 440m krone - and Onfi (clobazam) for Lennox-Gastaut syndrome which added